今年国庆、中秋长假期间，医美消费迎来一波高峰。中国商报记者走访多家医美机构发现，不少消费者利用假期践行"变美"计划，医美市场呈现供需两旺 态势。此外，男性消费者比例上升，选择进行植发、肉毒素注射（去皱、瘦脸）以及皮肤管理的男性明显增多。 当前，在医美市场上，一股追求理性与专业化的潜流在消费者中涌动。（资料图，图片由CNSPHOTO提供） "美丽投资"成焦点 男性消费者加速入场 10月2日上午11点，北京合生汇商圈的新氧线下门店内的候诊区已经坐了不少等待咨询和消费的顾客，其中不乏一些从外地来的"求美者"。 "平时工作太忙，恢复期也不方便，国庆长假正好有足够的时间来完成早就想做的项目，还不影响工作。"在候诊区的李薇（化名）告诉记者，她提前两个 月就预约了眼综合和注射微整形，预算在5万元左右。"这对我来说不是冲动消费，而是一项长期投资。" 像李薇这样的消费者并非个例。北京某连锁医美机构负责人张丽敏告诉记者，今年国庆前一周，平台下单量环比增长显著，搜索热度最高的项目包括热玛 吉、光子嫩肤、玻尿酸填充等轻医美项目。预约到店人数较多的城市包括北京、上海、广州、成都和杭州。 记者发现，今年国庆、中秋假期，医美消费呈现出一些 ...

中国商报（记者 马嘉）今年国庆、中秋长假期间，医美消费迎来一波高峰。中国商报记者走访多家医美机构发现，不少消费者利用假期践行"变美"计划， 医美市场呈现供需两旺态势。此外，男性消费者比例上升，选择进行植发、肉毒素注射（去皱、瘦脸）以及皮肤管理的男性明显增多。 "美丽投资"成焦点 男性消费者加速入场 10月2日上午11点，北京合生汇商圈的新氧线下门店内的候诊区已经坐了不少等待咨询和消费的顾客，其中不乏一些从外地来的"求美者"。 "平时工作太忙，恢复期也不方便，国庆长假正好有足够的时间来完成早就想做的项目，还不影响工作。"在候诊区的李薇（化名）告诉记者，她提前两个 月就预约了眼综合和注射微整形，预算在5万元左右。"这对我来说不是冲动消费，而是一项长期投资。" 值得关注的是，男性消费者的比例也在上升。有医美咨询师告诉记者："现在来做项目的男性，心态更加开放，目的性也很强，主要是为了解决脱发、皱纹 等具体问题。"此前就有数据显示，男性医美消费者增速连续多年高于女性。 节前新品集中上线 机构促销活跃市场 国庆、中秋假期前，医美市场已显露活跃态势。多款医美低价新品和促销活动赶在节前上线，覆盖射频、注射、皮肤管理等品类。比 ...

"立项指南通过'合并同类项'，将服务产出相似、价格水平相近的旧项目统一规范为新项目。"蒋炳 镇指出，这解决了各地价格项目不统一、价格水平不可比等问题。更深层次的意义在于，立项逻辑从按 操作细节立项转向按服务产出立项，新项目更多从患者获益角度衡量医疗技术价值，体现"价值决定价 格"的基本原理。 中新网北京9月26日电(记者 赵方园)9月25日，国家医保局举办医疗服务价格项目立项指南第四 场"美好生活专场"解读直播，覆盖妇科、产科、麻醉、康复、体被系统以及美容整形等六类立项指南。 中新健康记者注意到，新项目的设立从过去依据技术细节立项，转向以服务产出和价值为导向。 价值医疗为导向，从按技术细节立项转向按服务产出立项 国家医保局价格招采司医药价格处处长蒋炳镇透露，截至目前，国家医保局已印发33批立项指南， 整合设立主项目1640个、加收项599个、扩展项156个。 蒋炳镇表示，在编制和落实立项指南过程中，重点关注四大关系：旧项目与新项目、规范与进步、 增福祉与稳运行、保基础与促发展。 对于抓规范和推进步的关系，蒋炳镇介绍，在统一规范价格项目基础上，国家医保局持续关注临床 技术进步，通过适当放大价格项目的颗粒度、设置 ...

中新网北京9月26日电(记者赵方园)9月25日，国家医保局举办医疗服务价格项目立项指南第四场"美好 生活专场"解读直播，覆盖妇科、产科、麻醉、康复、体被系统以及美容整形等六类立项指南。 中新健康记者注意到，新项目的设立从过去依据技术细节立项，转向以服务产出和价值为导向。 价值医疗为导向，从按技术细节立项转向按服务产出立项 国家医保局价格招采司医药价格处处长蒋炳镇透露，截至目前，国家医保局已印发33批立项指南，整合 设立主项目1640个、加收项599个、扩展项156个。 国家医保局医药价格和招标采购指导中心唐菲表示，在编制妇科、产科、麻醉三类立项指南过程中，相 关部门坚持以服务产出为导向，体现技术劳务这一原则，突出人力价值、强化政策支持。 首先是坚持产出导向，适度整合，确保全国一盘棋。主要包括对部位的定义进行统一；对服务内容进行 统一；统一立项原则，尊重临床实际，体现技术难度。 如，将各地计价单位五花八门的"胎心监测"项目统一为"胎/次"，从顶层设计上引导地方成本测算时更 精准地体现产科医务人员的劳动价值。 其次是对技术创新的支持。通过"合并同类项"，将271项现行项目整合为124个主项目，更大颗粒度的设 计对 ...

本报讯 （记者张敏）9月25日，国家医保局举办医疗服务价格项目立项指南第四场"美好生活专场"解读直播，覆盖妇科、 产科、麻醉、康复、体被系统以及美容整形等六类立项指南。 国家医保局价格招采司医药价格处处长蒋炳镇介绍，国家医保局已印发33批立项指南，整合设立主项目1640个、加收项 599个、扩展项156个。 谈及增福祉和稳运行的关系，蒋炳镇表示，增进人民健康福祉和稳定医疗机构运行，两者相辅相成，是医疗服务价格立项 和定价的核心关切。立项指南将部分改善患者体验的诊疗服务单独立项或者设立加收项，既是为了引导医疗机构优化医疗服务 质量，也是为了支持医疗机构实现增量发展。 针对保基础和促发展的关系，蒋炳镇提到，国内医美需求尚未得到有效满足，市场前景比较广阔，有必要规范美容整形价 格项目。美容整形立项指南统一设立了101个主项目，覆盖"光子嫩肤""超声炮""热玛吉"等轻医美项目，以及填充、植发、隆 鼻、双眼皮等常见医美项目，后续各地还可以结合实际新增价格项目。 国家医保局统一规范美容整形价格项目的主要考虑是，适应大家对美好生活的向往，对更高颜值的追求，通过规范价格项 目，推动国内美容整形优质服务的供给，引导公立医疗机构 ...

本文来自微信公众号：新周刊 （ID：new-weekly），作者：张远山，编辑：陆一鸣，题图来自：视觉中国 周五下班，成群的年轻人飞往韩国，在两天内完成热玛吉、溶脂、填充等多个轻医美项目；周日晚上，带着红肿的脸返程。 在社交平台上，有人的行程更加极致，一天往返。在经验帖中，时间被划分得更加精确：北京时间7：50登机，韩国时间9：50下飞机直奔安检；11：30到 达医美机构面诊，14：00做完全部项目，19：45从韩国起飞。这位网友一天之内往返，她分享秘诀：选一个离机场近的医美机构。 每一小时的行程、每一个项目的顺序，都被精准规划——以短途旅行的预算，同时收获容貌的提升与工作的"刹车片"。 机票千元，签证通过率高达90%，项目价格仅为国内几分之一，中文顾问，一张床式服务，术后即时护理……如果不飞一趟韩国，你或许难以想象，韩国 医美已经为国内追逐美丽的人们打造出一条如何高效的通道。 对"小韩医美特种兵"而言，吸引他们的大概不只是几倍的价差，更是一种极速变美的新生活方式：无需请假，没有恢复期，甚至不影响周一例会。 这么近，那么美，周末去变美？ 7月初的一个周六，凌晨五点半，在微亮的天光里，孟圆从上海的家出发。8点1 ...

Core Viewpoint - The high-end skincare industry is facing significant challenges as consumers increasingly compare the value of expensive skincare products with medical beauty treatments, leading to a shift in spending preferences [3][4]. Group 1: Price Competition - A price war is intensifying in the medical beauty sector, with many institutions lowering prices to attract customers, resulting in a significant drop in treatment costs [8][10]. - Platforms like Meituan and JD are actively promoting medical beauty services, contributing to a downward trend in pricing and making services more accessible [10][12]. Group 2: Changing Consumer Demographics - The consumer base for medical beauty is becoming younger, with the post-95 and post-00 generations emerging as the main spending force, while the average spending per visit has decreased by 10% in 2024 [12][14]. - The shift towards more affordable medical beauty options is increasingly appealing to younger consumers, who are prioritizing cost-effective skincare solutions [12][18]. Group 3: Market Competition and Mergers - Competition among medical beauty companies is intensifying, with a focus on mergers and acquisition of agency rights, indicating a period of expansion in the market [13][14]. - The medical beauty market is projected to grow rapidly, reaching nearly 370 billion by 2025, with a compound annual growth rate of 17.4% since 2020 [14][18]. Group 4: Impact on High-End Skincare Brands - High-end skincare brands are losing market share, with over 20 billion in revenue lost over the past 4-5 years, as consumers question the value of premium products [14][16]. - The spending patterns of high-end beauty consumers are shifting, with entry-level and some mid-tier consumers moving towards medical beauty options, impacting the traditional luxury skincare market [16][18]. Group 5: Consumer Preferences and Decision-Making - Consumers are increasingly favoring medical beauty treatments that offer immediate results and scientific backing over traditional high-end skincare products that rely on emotional branding [23][24]. - The demand for effective and affordable medical beauty solutions is reshaping consumer decision-making, leading to a preference for treatments that provide better cost-effectiveness [23][24]. Group 6: Strategies of High-End Brands - High-end skincare brands are exploring new strategies, including enhancing product technology and integrating medical beauty channels to capture a share of the growing market [24][30]. - Some brands are adopting a differentiated approach, focusing on unique value propositions and exclusive services to retain high-net-worth customers [32][36].

Core Viewpoint - The article discusses the challenges faced by the company, Xinyang, as it transitions from an online medical beauty platform to a physical clinic model, highlighting the financial struggles and competitive pressures from larger platforms like Meituan and Douyin [4][10][15]. Financial Performance - In Q2 2025, Xinyang reported total revenue of 379 million yuan, a year-on-year decline of 7.0%, and a net loss of 36 million yuan compared to a net profit of 18.9 million yuan in the same period of 2024 [4]. - The total cost for Q2 2025 was 184.6 million yuan, up 19.0% from 155.1 million yuan in the previous year [4]. - Revenue from Xinyang's core business, "Information and Appointment Services," fell to 929 million yuan in 2024, a decrease of 19.36%, accounting for 63.37% of total revenue [10][11]. Business Transition - Xinyang launched its self-operated chain of clinics, SOYOUNG CLINIC, in November 2024, with 33 locations by August 2025, aiming for 50 by year-end [5][6]. - The shift to physical clinics has led to increased competition with former clients, resulting in further declines in online business [7][8]. Competitive Landscape - Xinyang faces significant competition from Meituan, which opened nearly 3,000 new medical beauty institutions in 2024, and Douyin, which has implemented various support policies for medical beauty services [13][14]. - The competition has led to a decrease in the number of medical service providers on Xinyang's platform, impacting its revenue [11][13]. Growth of Clinic Business - The chain business generated 170 million yuan in revenue in 2024, a staggering increase of 1,206%, with Q4 revenue reaching 81.27 million yuan, up 702% [15]. - The introduction of low-priced services, such as the "童颜针" (Youthful Needle), significantly boosted Xinyang's stock price, which rose 223% in a short period [15][16]. Operational Challenges - Rapid expansion of the clinic model has led to financial burdens, particularly in second-tier cities where patient volumes are lower [20]. - The average gross margin of 24% for the clinic business is considered unsatisfactory, and the CEO acknowledged the ongoing financial losses due to the clash between new and old business models [20][21]. Customer Dynamics - The dual role of Xinyang as both a platform and a service provider raises concerns about potential conflicts of interest and customer retention [23][24]. - While the clinic's standardized operations and competitive pricing are seen as strengths, there are concerns about the quality of service and customer satisfaction [26][27]. Industry Trends - The medical beauty industry is experiencing a slowdown, with a report indicating that 57% of consumers plan to maintain or increase their spending in 2025, down from 78% in 2024 [28].

Financial Performance - The company reported a significant improvement in operating cash flow, with a year-on-year increase of 300.52% [2] - Revenue from the cardiovascular interventional business reached 1.239 billion, a growth of 7.57% year-on-year [2] - The overall revenue and profit for the first half of the year remained stable compared to the previous year [2] Business Segments Medical Devices - The in vitro diagnostics and surgical anesthesia segments experienced slight declines in revenue due to increased competition and procurement rhythms [2] - The skin care business aims for sales of 500-600 million in 2026, with a net profit margin of 45-50% [3] Innovative Drugs - The innovative drug segment is the largest in terms of R&D investment, focusing on metabolic diseases [4] - The company is optimistic about the potential of its innovative drugs, particularly in weight management and metabolic disorders [4] Strategic Adjustments - The company has undergone organizational restructuring to stabilize its performance after a period of significant fluctuations [2] - Future growth is expected to be driven by strategic emerging business segments, including dermatology and innovative drugs [2] Market Strategy - The company plans to maintain a sales expense ratio below 20% for its medical aesthetics products, focusing on scientific and cost-effective marketing strategies [8] - The pricing strategy for the "童颜针" (youthful needle) series aims to capture a broader market by offering competitive pricing [15] Regulatory and Competitive Landscape - The company anticipates a reduction in prices for drug-coated balloons due to procurement policies, which may increase market penetration [9] - The competitive landscape for GLP-1 drugs is intensifying, but the company remains confident in its product competitiveness [20] Future Outlook - Analysts project a net profit of around 1 billion for the current year, with a stable outlook for the formulation business [2] - The company aims for a revenue growth of 10-15% next year, driven by structural heart disease and pharmaceutical products [2]

Core Viewpoint - The establishment of a unified pricing guideline for cosmetic surgery in China aims to create a more transparent and orderly market environment, enhancing safety and consumer confidence in the beauty industry [1][3][10]. Group 1: Market Overview - The cosmetic surgery market in China is projected to reach nearly 300 billion yuan by 2024, indicating significant market vitality and potential [1]. - The new pricing guideline is expected to standardize pricing projects, making medical bills clearer for consumers and reducing confusion in the pricing of cosmetic procedures [3][5]. Group 2: Pricing Standardization - The National Healthcare Security Administration has released a guideline that unifies pricing projects for cosmetic surgery, allowing medical institutions to set reasonable prices independently [3][5]. - The guideline aims to simplify the naming of procedures, making it easier for consumers to understand the technical principles behind treatments [5][6]. Group 3: Inclusion of New Technologies - The pricing guideline is designed to accommodate new technologies and materials in the cosmetic surgery field, allowing for the inclusion of various new injection materials under the same pricing project [6][7]. - Medical institutions are permitted to establish additional charges for new services, enhancing their ability to meet personalized consumer demands [7]. Group 4: Emphasis on Quality and Safety - The guideline reflects the value of technical skills and labor in cosmetic procedures, promoting overall improvement in the quality of medical services [10]. - It is emphasized that cosmetic surgery is a medical practice with inherent risks, and consumers are encouraged to choose reputable medical institutions and experienced practitioners [10].